View Older Stories View More Recent Stories

Aug 1, 2024 07:30AM Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024
Jul 2, 2024 07:30AM Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
May 9, 2024 07:30AM Trevi Therapeutics to Participate in Upcoming Conferences
May 7, 2024 04:05PM Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 1, 2024 04:05PM Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
Apr 9, 2024 07:30AM Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Apr 4, 2024 07:30AM Trevi Therapeutics to Participate in Upcoming April Events
Apr 2, 2024 07:32AM Trevi Therapeutics (TRVI) Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Apr 2, 2024 07:30AM Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Mar 20, 2024 04:05PM Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Mar 13, 2024 04:05PM Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
Feb 28, 2024 07:30AM Trevi Therapeutics to Participate in Upcoming March Events
Feb 6, 2024 07:30AM Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Jan 4, 2024 07:33AM Trevi Therapeutics (TRVI) Provides Business Updates
Jan 4, 2024 07:30AM Trevi Therapeutics Provides Business Updates
Dec 5, 2023 07:30AM Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
Nov 9, 2023 04:05PM Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
Nov 2, 2023 07:30AM Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough
Nov 1, 2023 04:05PM Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023
Oct 13, 2023 08:30AM Trevi Therapeutics (TRVI) Reports Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio
Oct 13, 2023 08:30AM Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis
Sep 6, 2023 07:30AM Trevi Therapeutics to Participate in Upcoming September Events
Aug 10, 2023 04:05PM Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update
Aug 3, 2023 04:05PM Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023
Aug 1, 2023 07:30AM Trevi Therapeutics to Participate in Upcoming August Events
Jul 6, 2023 07:30AM Trevi Therapeutics to Participate in Upcoming July Investor Events
May 30, 2023 07:30AM Trevi Therapeutics to Participate in Upcoming June Conferences
May 22, 2023 04:05PM Trevi Therapeutics (TRVI) Announces Publication of Positive Data from the CANAL Trial
May 22, 2023 04:05PM Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence
May 11, 2023 04:05PM Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
May 9, 2023 07:30AM Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023
May 4, 2023 04:05PM Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023
May 2, 2023 07:30AM Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference
Apr 27, 2023 07:30AM Trevi Therapeutics to Participate in Upcoming May Investor Events
Apr 11, 2023 04:05PM Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
Mar 16, 2023 04:05PM Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
Mar 9, 2023 04:05PM Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023
Mar 8, 2023 07:32AM Trevi Therapeutics (TRVI) Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
Mar 8, 2023 07:30AM Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
Mar 6, 2023 04:05PM Trevi Therapeutics to Participate in Upcoming March Conferences
Feb 21, 2023 07:00AM Presenting on the Emerging Growth Conference on February 22 Register Now
Feb 16, 2023 07:30AM Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023
Feb 2, 2023 07:30AM Trevi Therapeutics to Present and Participate in Upcoming February Conferences
Jan 25, 2023 09:00AM Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio(TM) with The Stock Day Podcast
Jan 5, 2023 04:05PM Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences
Dec 19, 2022 04:05PM Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference
Nov 14, 2022 04:06PM Trevi Therapeutics (TRVI) Appoints David Clark as Chief Medical Officer
Nov 14, 2022 04:05PM Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer
Nov 10, 2022 04:05PM Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
Nov 8, 2022 07:30AM Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference
View More Recent Stories View Older Stories